1 March 2023 The COVID-19 pandemic turned the spotlight on the South African Health Products Regulator (SAHPRA), with many people expecting the regulator to approve medication that would see the end to the virus, but more often with limited understanding of the processes involved in reaching...
The Radiation Control Unit of the South African Health Products Regulatory Authority (SAHPRA) hosted an engagement with Inspection Bodies. We have invited several Inspection Bodies to share their knowledge, experience, and expertise to begin this conversation focusing on the: Accreditation process by the South African National Accreditation...
Pretoria, 23 February 2023 - The South African Health Products Regulatory Authority (SAHPRA) hosted the Regional Quality Management Systems (QMS) Technical Working Group Workshop during 20 - 23 February 2023 at Protea Hotel – OR Tambo Airport. The participating countries included: Angola, Botswana, Eswatini, Lesotho,...
17 February 2023 Pretoria - The South African Health Products Regulatory Authority (SAHPRA) Radiation Control (RadCon) Unit has undergone intensive training on the Regulatory Authority Information System (RAIS+) through the International Atomic Energy Agency (IAEA). The training took place at the head office in Pretoria...
The South African Health Products Regulatory Authority (SAHPRA) hosted a conversation on what medication errors are and why it is vital that patients or healthcare professionals report them. We have invited panellists from two hospitals to share their knowledge, experience, and expertise to begin this important...
Pretoria, 30 January 2023 – The South African Health Products Regulatory Authority (SAHPRA) has registered Paxlovid, an anti-viral medicine manufactured by Pfizer, to treat COVID-19. Paxlovid, which contains Nirmatrelvir (150mg) and Ritonavir (100mg), is a medicine that is used for the treatment of mild to moderate...
09 January 2023 Note to Radionuclides Authority Holders The Annual Returns have been somewhat delayed and are now being sent out. It is a time-consuming process and will not be completed before 21 January 2023. Please await the prepopulated form for year-end 2022 (AR22) and do not resort...
Many of you have heard about this strange sounding medication, Cabotegravir (Cah-bot-er-grah-ver), floating around news broadcasts and print outlets. Well, this medication is a Human Immunodeficiency Virus (HIV) anti-retroviral (ARV) that has been recently approved by the South African Health Products Regulatory Authority (SAHPRA). What is...
Pretoria, 2 December 2022 – The South African Health Products Regulatory Authority (SAHPRA) has registered Cabotegravir (Apretude 600 mg/3ml injection), a long-acting HIV pre-exposure prophylactic. Cabotegravir is an antiretroviral drug (ARV) that people living with HIV may use, together with other ARVs, to keep the virus...
Pretoria, 2 December 2022 – With the establishment of the South African Health Products Regulatory Authority (SAHPRA) in February 2018, the regulatory authority inherited a backlog of approximately 16 000 new product and variation applications from its predecessor, the Medicines Control Council (MCC). As is generally...
